What we develop
Sensorion’s mission is to offer innovative therapeutic solutions that provide long-term improvements to the lives of patients suffering from, or at risk of, inner ear disorders. In striving to fill this significant unmet medical and social need, we are continuously developing and optimizing our pipeline, mobilizing our in-house technology platform, scientific expertise, and network of experts.
| Program | Indication | Discovery | In vivo PoC | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Next steps |
|---|---|---|---|---|---|---|---|---|
| RESTORE | ||||||||
| SENS-601 | Congenital onset | 100 | 100 | 100 | 30 | 0 | 0 | CTA clearance in France, review in Canada | US IND and Australian CTA in preparation |
| SENS-601 | Childhood onset | 100 | 100 | 90 | 0 | 0 | 0 | CTA/IND Enabling Activities |
| SENS-601 | Adult onset | 100 | 100 | 90 | 0 | 0 | 0 | CTA/IND Enabling Activities |
| TREAT AND PREVENT | ||||||||
| SENS-401 Cochlear | Hearing preservation after cochlear implantation | 100 | 100 | 100 | 100 | 100 | 0 | Exploring partnering options |
| SENS-401 CIO | Cisplatin-Induced Ototoxicity | 100 | 100 | 100 | 100 | 30 | 0 | Exploring partnering options |
| SENS-401 SSNHL | Sudden Sensorineural Hearing Loss | 100 | 100 | 100 | 100 | 100 | 0 | Exploring partnering options |
PRODUCTS
04 67 20 77 30
Go to the description